Considering that systemic inflammation and abnormal glucose and lipid metabolism coexist and interact in COPD patients, chemerin's role as a regulator of inflammation and lipid metabolism makes it a potentially highly relevant target for COPD treatment and rehabilitation. Here, RARRES2 is linked to chronic obstructive pulmonary disease.